MUMBAI, India, Oct. 20, 2022 /PRNewswire/ -- Piramal Pharma Limited (PPL) today announced that Yapan Bio has expanded its capabilities with a new process development facility in Genome Valley, Hyderabad, India.
PPL has a strategic minority interest in Yapan and markets its services through Piramal Pharma Solutions (PPS), an industry-leading, patient-focused contract development and manufacturing organization (CDMO) serving the global pharmaceutical and biotech market. .
With this expansion, Yapan has enhanced its ability to support the comprehensive development and manufacturing of gene therapy products, RNA and DNA from plasmids. The expansion includes three upstream suites (including biosafety level 2 containment), a downstream process development lab, an analytical development lab, and supporting infrastructure. The new laboratories will allow Yapan to optimize the use of GMP facilities to support the manufacture of clinical trial material for customers.
The new facility was inaugurated by K.T. Rama Rao, Minister of Municipal Administration and Urban Development, Industries and Commerce and Information Technology of Telangana; Nandini Piramal, President, Piramal Pharma Ltd; Harinder S. Sikka, Group Director, Strategic Businesses, Piramal Enterprises Limited; and Atin Tomar
The Honorable Minister K.T. Rama Rao stated, "It is encouraging to see that Yapan Bio and Piramal Pharma have been continuously expanding from Genome Valley. This is testament to the strength of the Telangana biotech industry. The State of Telangana has been working with the industry to see how to better tailor our policies and incentives to their ever-evolving needs. We will continue to be a partner for growth and ensure that companies like Yapan Bio continue to grow from the cluster."
Nandini Piramal, spokesperson for Piramal Pharma Ltd, commented: "This new facility, part of our $8 million expansion plan for Yapan Bio, represents the first major step in the Piramal/Yapan partnership since our initial investment in December. of 2021. It is proof of our commitment to Yapan and the large molecule CDMO business, as well as our commitment to patients.With this investment, the Yapan team can carry out a greater number of projects than before, which resulting in the development and delivery of more novel products for clinical evaluation and, ultimately, faster and better treatments for patients."
About Piramal Pharma Limited:
Piramal Pharma Limited (PPL) offers a portfolio of differentiated products and services through end-to-end manufacturing capabilities in 15 global facilities and a global distribution network in more than 100 countries. PPL includes Piramal Pharma Solutions (PPS), an integrated contract manufacturing and development organization; Piramal Critical Care (PCC), a Complex Hospital Generics business; and the India Consumer Healthcare business, which sells over-the-counter products. In addition, it has a joint venture with Allergan, the ophthalmology leader in the Indian formulation market. In October 2020, PPL received a 20% strategic growth investment from the Carlyle Group.
For more information visit: https://www.piramal.com/pharma/, Facebook, Twitter, LinkedIn
About Piramal Pharma Solutions:
Piramal Pharma Solutions (PPS) is a contract development and manufacturing organization (CDMO) providing end-to-end development and manufacturing solutions throughout the drug life cycle. We serve our customers through a globally integrated network of facilities in North America, Europe and Asia. This allows us to offer a wide range of services including drug discovery solutions, pharmaceutical and process development services, clinical trial supplies, commercial API supply and finished dosage forms. We also offer specialized services such as the development and manufacturing of highly potent APIs, antibody and drug conjugates, sterile fill/finish, peptide products and services, and potent solid oral pharmaceuticals. PPS also provides biologics development and manufacturing services, including vaccines, gene therapies and monoclonal antibodies, made possible by Piramal Pharma Limited's investment in Yapan Bio Private Limited. Our track record as a trusted service provider with expertise in a variety of technologies makes us the partner of choice for innovative and generic companies around the world.
For more information visit: www.piramalpharmasolutions.com | Twitter | LinkedIn
Made at Acerca Bio Pvt Ltd
Headquartered in Genome Valley in Hyderabad, India, Yapan Bio has a proven track record of success as a Contract Development and Manufacturing Organization (CDMO) for large molecules. Yapan provides process development, scale-up, and cGMP-compliant manufacturing of vaccines and biological/biotherapeutic products, including high-containment product classes (up to BSL-2 ), recombinant vaccines, RNA/DNA vaccines, gene therapies, monoclonal antibodies, protein therapeutics and other complex biological products. Yapan's founders, Atin Tomar and Nirav Desai, have over 40 years of combined experience in the global biotech industry, specializing in the fields of developing, manufacturing and commercializing vaccines and biologics/biotherapeutics. In 2021, Piramal Pharma Solutions made an equity investment in Yapan Bio, allowing Yapan to take the business into its next phase of growth.
For more information, visit: https://www.yapanbio.com | LinkedIn
Photo: linkPhoto: linkPhoto: linkPhoto: linkPhoto: linkLogo: linkLogo: linkLogo: link
View original content: enlace
